Background: TSEN (MNS33) is a low-incidence antigen in the MNS blood group system encoded by hybrid glycophorin genes. TSEN is expressed by a unique amino acid sequence that results from the junction of GPA58 to GPB27, if the GPB carries S antigen. Until this study, only one example of anti-TSEN had been found. Antibody screening red blood cells (RBCs) positive for both S and s (ref. No. C873) reacted with four patient sera. Initially, the RBCs had been typed as S+s+, but later were typed as S–s+ in another laboratory. Two other RBC samples, one from a volunteer blood donor (D.L.), the other from a patient whose serum contained anti-EnaFR (J.S.), also gave anomalous results when tested with anti-S. We suspected the presence of TSEN-positive hybrids on all three RBC samples. Materials and Methods: Reactive sera (O.B., E.C., S.K., R.F.) were tested against RBCs with normal MNS phenotypes and with TSEN-positive RBCs. The RBCs of D.L., J.S. and C873 were tested with anti-S whose reactivity with S+s+ TSEN+ RBCs had been established previously, and with the original example of anti-TSEN. Immunoblotting was performed on the C873, D.L. and J.S. RBC membranes using a monoclonal antibody to an epitope common to both glycophorin A and glycophorin B. Results: The sera from O.B., E.C., S.K. and R.F. were strongly reactive on the indirect antiglobulin test with TSEN+ RBCs. The RBCs of C873, D.L. and J.S. were typed as TSEN+. Immunoblotting pattern of D.L. and C873 were consistent with TSEN heterozygotes, while that of J.S. was consistent with a TSEN homozygote. Conclusions: Based on the estimated number of screening events with C873 RBCs, the incidence of anti-TSEN is approximately 1 in 20,000 sera. The antibody is found in patients with and without documented exposure to allogeneic RBCs. All known examples of anti-TSEN are IgG, but their clinical significance is not known.

1.
Reid ME, Moore BP, Poole J, Parker NJ, Asenbryl E, Vengelen-Tyler V, Lubenko A, Galligan B: TSEN: A novel MNS-related blood group antigen. Vox Sang 1992;63:122–128.
2.
Johe KK, Smith AJ, Vengelen-Tyler V, Blumenfeld OO: Amino acid sequence of an α-δ-glycophorin hybrid. A structure reciprocal to Sta δ-α-glycophorin hybrid. J Biol Chem 1989;264:17486–17493.
3.
Storry JR, Poole J, Condon J, Reid ME: Identification of a novel hybrid glycophorin gene encoding GP.Hop. Transfusion 2000;40:560–565.
4.
Reid ME, Poole J, Green C, Neill G, Banks J: MINY: A novel MNS-related blood group antigen. Vox Sang 1992;63:129–132.
5.
Halverson GR, Reid ME, Sutherland J, Rhodes M: Evaluation and comparison of three human monoclonal anti-S, two human polyclonal anti-S and one murine anti-GPB. Immunohematology 1999;15:163–166.
6.
Hemming NJ, Reid ME: Evaluation of monoclonal anti-glycophorin B as an unusual anti-S. Transfusion 1994;34:333–336.
7.
Dodge JT, Mitchell C, Hanahan DJ: The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes. Arch Biochem Biophys 1963;100:119–130.
8.
Reid ME, Lomas-Francis C, Daniels GL, Chen V, Shen J, Ho YC, Hare V, Batts R, Yacob M, Smart E, Green CA: Expression of the erythrocyte antigen Henshaw (He; MNS6): Serological and immunochemical studies. Vox Sang 1995;68:183–186.
9.
Issitt PD, Daniels G, Tippett P: Proposed new terminology for Ena. Transfusion 1981;21:473–474.
10.
Chandanyingyong D, Pejrachandra S: Studies on the Miltenberger complex frequency in Thailand and family studies. Vox Sang 1975;28:152–155.
11.
Metaxas-Buehler M, Metaxas MN, Sturgeon P: MNSs and Miltenberger frequencies in 211 Chinese. Vox Sang 1975;29:394–399.
12.
Race RR, Sanger R: Blood Groups in Man, ed 6. Oxford, Blackwell, 1975.
13.
Lubenko A: Anti-S sera and their co-existing ‘private antibodies’ (abstract 01-17). Fifth Annual Scientific Meeting, British Blood Transfusion Society, Stirling, 1987.
14.
Issitt PD, Anstee DJ: Applied Blood Group Serology, ed 4. Durham, Montgomery, 1998.
15.
Dahr W, Beyreuther K, Steinbach H, Gielen W, Krüger J: Structure of the Ss blood group antigens. II. A methionine/threonine polymorphism within the N-terminal sequence of the Ss glycoprotein. Hoppe Seylers Z Physiol Chem 1980;361:895–906.
16.
Storry JR, Reid ME: Synthetic peptide inhibition of anti-S (abstract). Transfusion 1996;36(suppl):55S.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.